Insider Selling: Evolus, Inc. (NASDAQ:EOLS) Insider Sells 111,323 Shares of Stock

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 111,323 shares of the firm’s stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $10.05, for a total transaction of $1,118,796.15. Following the completion of the sale, the insider now owns 381,509 shares of the company’s stock, valued at $3,834,165.45. This trade represents a 22.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

David Moatazedi also recently made the following trade(s):

• On Monday, June 16th, David Moatazedi sold 16,582 shares of Evolus stock. The shares were sold at an average price of $9.89, for a total value of $163,995.98.
• On Monday, May 12th, David Moatazedi sold 15,787 shares of Evolus stock. The shares were sold at an average price of $9.87, for a total value of $155,817.69.
• On Thursday, March 27th, David Moatazedi sold 6,251 shares of Evolus stock. The shares were sold at an average price of $12.40, for a total transaction of $77,512.40.

Evolus Price Performance

Shares of Evolus stock traded up $0.03 on Monday, reaching $9.96. 762,050 shares of the stock were exchanged, compared to its average volume of 742,318. The firm’s 50 day moving average is $10.31 and its 200-day moving average is $11.77. The firm has a market cap of $642.18 million, a PE ratio of -10.94 and a beta of 1.00. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. Evolus, Inc. has a one year low of $8.67 and a one year high of $17.82.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on EOLS shares. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Thursday, May 8th. BTIG Research initiated coverage on shares of Evolus in a research report on Thursday, April 17th. They set a “buy” rating and a $21.00 price target on the stock. Barclays lifted their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Finally, HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of Evolus in a research report on Thursday, April 10th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $23.75.

Institutional Investors Weigh In On Evolus

A number of large investors have recently modified their holdings of the business. Tang Capital Management LLC raised its holdings in shares of Evolus by 3.1% during the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company’s stock worth $55,171,000 after buying an additional 150,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in Evolus by 2.0% in the first quarter. Vanguard Group Inc. now owns 3,234,068 shares of the company’s stock valued at $38,906,000 after buying an additional 62,664 shares in the last quarter. Nantahala Capital Management LLC raised its stake in Evolus by 10.8% during the fourth quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company’s stock worth $34,557,000 after acquiring an additional 305,300 shares in the last quarter. Caligan Partners LP raised its stake in Evolus by 22.7% during the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock worth $29,724,000 after acquiring an additional 498,900 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Evolus by 1.7% in the first quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock worth $16,746,000 after acquiring an additional 23,605 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.